ArticleEuropean spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society2025
The impact of proton pump inhibitor use on fusion rates following single-level lumbar spinal fusion surgery.
Article in European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Testosterone Replacement Therapy is Associated With Increased Risk of Pseudarthrosis After Single-Level Anterior Cervical Discectomy and Fusion: A Propensity Matched Analysis.Global spine journal · 2026Article
- Proton pump inhibitors are associated with increased risk of pseudoarthrosis after lumbar fusion.North American Spine Society journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLumbar spinal fusion surgery is a common treatment for degenerative spinal conditions. While proton pump inhibitors (PPIs) are widely prescribed for acid-related disorders, emerging evidence suggests that PPI use may negatively affect bone health, potentially influencing spinal fusion outcomes. This study evaluates the impact of postoperative proton pump inhibitor (PPI) use on fusion rates following single-level lumbar spinal fusion surgery.
methodsData were obtained from the Global Collaborative Network on the TriNetX platform. Patients undergoing single-level lumbar fusion were identified using ICD and CPT codes. Propensity score matching was employed to balance demographics and comorbidities between PPI users and non-users. Postoperative PPI use was defined as continuous use for at least three months following surgery. Non-fusion was identified using ICD-10 code M96.0 at six months, one year, and two years post-surgery. Odds ratios (OR) and 95% confidence intervals (CI) were calculated to assess the risk of pseudarthrosis.
resultsThe study included 3,857 PPI users and 4,4291 non-users, reduced to 3,847 in each group after propensity score matching. PPI users showed a significantly higher risk of non-fusion at six months (OR: 1.82, 95% CI: 1.54-2.16), one year (OR: 2.08, 95% CI: 1.78-2.44), and two years (OR: 2.33, 95% CI: 2.01-2.71) compared to non-users.
conclusionThe study indicates that postoperative PPI use is linked to a higher risk of non-fusion after lumbar spinal fusion surgery. Clinicians may need to weigh the benefits of postoperative PPI use against its potential impact on bone healing.
Indexed as
Identifiers
40442516What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.